Efficacy of Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+3TC) Versus Dolutegravir Plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at 48 Weeks in Antiretroviral Naïve Women: GEMINI Studies Subgroup Analysis

Abstract